Turning down the ammonia dial: Phase 2a evidence for YAQ007 in cirrhosis.
Erickson Hanna H
Probiomed · IFNAR2 · Recombinant Proteins
interferon alfa-2a is a recombinant proteins developed by Probiomed. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection or subcutaneous injection.
| Brand Names | Proquiferon |
| Company | Probiomed |
| Drug Class | Recombinant Proteins |
| Molecular Target | IFNAR2 |
| Route | Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection |
| Status | Approved |
interferon alfa-2a acts on 1 molecular target:
| IFNAR2 | interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC) |
interferon alfa-2a is developed for 8 unique indications across 2 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Infections and infestations | Acquired immunodeficiency syndrome | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Hairy cell leukaemia | ✓ Approved |
| Infections and infestations | Hepatitis B | ✓ Approved |
| Infections and infestations | Hepatitis C | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Kaposi's sarcoma | ✓ Approved |
+3 more indications available with a free account
Sign up free to view all indications →Erickson Hanna H
Ambrosino Alessia A, Patrone Deanira D, Moriello Claudia C, Al-Sammarraie Sura Hilal Ahmed SHA et al.
In Figure 2A of the original publication [...].
Nampoothiri Sreekala S, Fernandois Daniela D, Journiac Nathalie N, Delahaye Fabien F et al.
Sex-specific differences in metabolic and immune function are shaped by endocrine-immune interactions, yet the complexity of this relationship remains poorly understood. Here, we identify an immune cell-like state of tanycytes, an ependymoglial cell type lining the third ventricle that mediates brain-body communication1,2 in both mice and humans. Using single-cell transcriptomics, we provide a high-resolution cellular map of the mouse and human mediobasal hypothalamus with cross-species comparison of tanycytes. We capture dynamic sex-, oestrous cycle- and high-fat diet-dependent transcriptomic changes in tanycytes, including a cyclic interferon response in tanycytes during the physiological oestrous cycle in female mice. We found that the oestrous cycle, with its changing hormonal milieu, especially oestradiol, affected the brain's immune responses, characterized by the temporal and cyclic expression of interferon regulatory factor 7 (Irf7) gene, as well as downstream interferon-stimulated genes such as Cxcl10 in tanycytes of female mice, which are associated with increased infiltration of leukocytes and cytokine responses. Irf7 expression in tanycytes of physiological males remained stable and markedly lower, suggesting a distinct immune activation pattern in the brains of cycling females. By targeting oestrogen and interferon signaling in tanycytes, we show that balanced, cyclic leukocyte infiltration into the median eminence may have a role in oestrous cycle maintenance, whereas Irf7 in tanycytes modulates circulating monocyte proportions, revealing brain-immune system communication through tanycytes. Our findings reveal an immune-associated role for tanycytes, with potential implications for understanding the endocrine and immunological mechanisms underlying sex-biased diseases.
White Maleana G MG, Iordanskiy Sergey S
Activation of cytosolic RNA and DNA sensing pathways that normally recognize viral nucleic acids triggers the expression and release of type I interferons (IFN-I). This release drives the expression of interferon-stimulated genes (ISGs) that activate acute inflammation and counteract viral replication at various stages. Recent studies have highlighted how interferon-stimulated gene 15 (ISG15), a small, ubiquitin-like modifier, regulates cytosolic RNA and DNA sensing pathway proteins to control the antiviral response and inflammation. ISG15 is a multifunctional protein that acts as a secreted cytokine, binds freely to intracellular proteins, and covalently modifies proteins in a reversible process termed ISGylation. A dual regulatory molecule, ISG15 can both stabilize and destabilize proteins that promote and inhibit IFN-I signaling. Conversely, viruses have evolved strategies to disrupt and exploit ISG15-dependent antiviral responses to evade the host immune system. In this review, we examine how ISG15 regulates cytosolic RNA and DNA sensing pathway proteins to control IFN-I signaling and the antiviral response, highlighting it as a master regulator that fine-tunes IFN-I signaling and feedback. Recognizing the multifaceted action of ISG15 is essential for designing balanced therapeutic strategies across antiviral drug development, cancer immunotherapy, and chronic inflammatory disease management.
Baker Jacob J JJ, Kogan Emily E, Ma Shaorong S, Lu Ju J et al.
It is unclear how serotonin 2A receptors (5-HT2ARs) in cortical layer 5 pyramidal neurons differentially contribute to psilocybin-induced hallucinations versus neuroplasticity. Here we show that psilocybin promotes synapse formation and maturation while accelerating the elimination of pre-existing synapses. Cell type-specific manipulation further demonstrated that 5-HT2AR signaling in cortical layer 5 pyramidal neurons is necessary and sufficient for psilocybin-induced synaptic remodeling but dispensable for the head-twitch response, a rodent proxy of hallucination.
Farzat Mahmoud M, Kachanov Mykyta M, Vetterlein Malte W MW, Salomon Georg G et al.
Background/objective: Urinary continence recovery after robot-assisted radical prostatectomy remains variable despite technical refinements intended to preserve function. We describe Total en bloc Urethra Preservation at Robot-assisted Prostatectomy (ToP-RAP), a technique that preserves the entire intraprostatic urethra and avoids urethral transection, and report short-term functional and oncological outcomes. Methods: Patients with PSA ≤ 15 ng/mL, prostate volume ≤ 80 mL, biopsy ISUP grade ≤ 3, and predefined selection criteria underwent surgery in this single-arm, two-center, IDEAL stage 1-2a development study (ClinicalTrials.gov NCT07678489). Surgical, perioperative safety, continence, and oncological outcomes based on PSA, imaging, and secondary treatment were assessed descriptively. Results: The first 16 consecutive patients were treated between 02/2024 and 05/2025. Median age was 66 years (IQR 62-71), PSA was 6.7 ng/mL (IQR 4.7-9.6), and prostate volume was 33 mL (IQR 29-46). Biopsy ISUP grades 1, 2, 3 were in 19%, 44%, and 38% of patients, respectively. On MRI, 38% of patients had multifocal bilateral lesions. Urethral repair of ≤1 cm was required in 13% of patients. All patients underwent at least interfascial nerve sparing. One posterolateral positive surgical margin and one perioperative complication (fascial dehiscence) occurred, no further complications were observed within 90 days. Median follow-up was 7.2 months (IQR 6.1-10.7). No patient had PSA persistence, biochemical recurrence, or secondary treatment. Overall, 15 of 16 patients (94%) recovered urinary continence, and 94% did so within 5 days. Limitations include the small cohort and short follow-up. Conclusions: Early findings support the feasibility and short-term safety of ToP-RAP. The observed early continence recovery warrants evaluation in larger cohorts with longer follow-up.
+9996 more articles available with a free account
Sign up free to view all articles →